For the first time in decades, novel urinary tract infection (UTI) treatments and vaccines are making significant progress worldwide.
Recce Pharmaceuticals Ltd today announced positive data from a Phase I/II clinical trial for UTIs and urosepsis, demonstrating that RECCE® 327 (R327) administered intravenously is safe and efficacious against Escherichia coli (E. coli).
New UTI Treatments Confirm Positive Advances in 2024
CDC Advises Updated COVID Vaccine for Everyone Over 6 Months of Age
By Robin Foster HealthDay ReporterFRIDAY, June 28, 2024 (HealthDay News) — As a summer wave of COVID infections rolls across the country, U.S. health officials have recommended that all Americans …